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Abstract
Background and Aim—Hepatocyte apoptosis or necrosis from accumulation of bile salts may 
play an important role in the disease progression of primary sclerosing cholangitis (PSC). The aim 
of the current study was to measure serum markers of hepatocyte apoptosis (cytokeratin 18 
fragments - K18) and necrosis (high-mobility group protein B1 - HMGB1) in adults with PSC and 
examine the relationship with disease severity.
Methods—We measured serum levels of K18 and HMGB1 in well phenotyped PSC (N=37) and 
39 control subjects (N=39). Severity of PSC was assessed biochemically, histologically and PSC 
Mayo Risk Score. Quantification of hepatocyte apoptosis was performed using TUNEL assay.
Results—The mean age of the study cohort was 49.7 ± 13.3 years and comprised of 67% men 
and 93% Caucasian. Serum K18 levels were significantly higher in the PSC patients compared to 
control (217.4 ± 78.1 vs. 157.0 ± 58.2 U/L, p-val=0.001). However, HMGB1 levels were not 
different between the two groups (5.38 ± 2.99 vs. 6.28 ± 2.85 ng/mL, p-val=0.15). Within the PSC 
group, K18 levels significantly correlated with AST (r=0.5, p-val=0.002), alkaline phosphatase 
(r=0.5, p-val=0.001), total bilirubin (r=0.61, p-val= <0.001), and albumin (r=−0.4, p-val =0.02). 
Serum K18 levels also correlated with the level of apoptosis present on the liver biopsy (r=0.8, p-
val = <0.001) and Mayo Risk score (r=0.4, p-val=0.015).
Conclusion—Serum K18 but not HMGB1 levels were increased in PSC and associated with 
severity of underlying liver disease and the degree of hepatocyte apoptosis.
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INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by fibrosis of 
intra- and/or extra- hepatic biliary tree resulting in the development of diffuse biliary 
strictures [1,2]. Biliary structuring leads to intrahepatic cholestasis that can lead to 
cholangiocyte and hepatocyte cell death. The precise pathophysiologic mechanisms through 
which this occurs, however, remains unclear. Liver has a large population of immune cells 
including Kupffer cells, natural killer (NK) cells, and natural killer-T (NKT) cells that 
produce signaling molecules such as tumor necrosis factor alpha (TNF-α), TNF-related 
apoptosis-inducing ligand (TRAIL) and Fas ligand [3–5]. These molecules often perpetuate 
the initial injury from intrahepatic cholestasis through apoptotic pathways from 
accumulation of endogenous toxic bile acids [6]. One study that examined explanted liver 
tissue of primary biliary cirrhosis (PBC) and PSC patients showed that apoptosis in the bile 
ducts was significantly increased in PBC and not PSC patients [7]. Therefore, it has been 
suggested that apoptosis did not play a central role in PSC [8]. However, a recent study 
measured several serum markers of apoptosis (soluble Fas, M30 and M65) in patients with 
immune-mediated liver diseases and reported that patients with PSC had increased serum 
markers of apoptosis that correlated with disease activity [9].
Biochemically, apoptosis is commonly initiated and executed by activation of intracellular 
enzymes termed caspases [10]. Hepatocytes contain in their cytoplasm, a cytoskeletal 
system consisting of intermediate filament proteins primarily made up of keratins, K8 
(previously called CK8) and K18 (previously called CK18) which play an important 
functional role in the integrity and mechanical stability [10–12]. Induction of apoptosis in 
liver disease results in early cleavage of K18 by caspases [10]. These fragments are stable to 
proteolysis and are released into the circulation after hepatocyte plasma membrane 
disintegration during later stages of apoptosis [10]. The serum K18 fragment levels can be 
measured by a commercially available ELISA assay, and has shown to be altered in some 
liver disorders associated with hepatic inflammation and injury [9,13,14].
Hepatocyte death can also occur through necrosis, but the role of hepatocyte necrosis in liver 
disorders such as PSC is currently not known. Necrosis involves cell death through autolysis 
and results in disruption of the integrity of cellular membranes leading to the uncontrolled 
release of cell contents [15]. Unlike apoptosis, caspase activation does not occur in necrosis. 
High mobility group box 1 (HMGB1) is a chromatin protein that directly interactions with 
nucleosomes [16,17]. HMGB1 is involved in the regulation of expression of several genes 
[18]. HMGB1 is released when a cell undergoes necrosis as the nuclear and cytoplasmic 
membranes lose their integrity [18,19]. Little HMGB1 is released by cells undergoing 
apoptosis as it is bound to nucelosomes in apoptotic bodies [20]. HMGB1 is also actively 
secreted by cells of the innate immune system such as monocytes and macrophages and acts 
as a proinflammatory cytokine [21,22]. To date, no studies have been conducted to assess 
serum markers of necrosis in PSC.
Many aspects of the pathophysiology of PSC remain unclear. Although inflammation and 
fibrosis in PSC are initially focused on the biliary system, the death of hepatocytes is an 
important component of the disease progression [9]. However, the precise mechanism 
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through which hepatocyte injury occurs remains unclear. In particular, the relative 
contributions of apoptosis and necrosis in PSC are not well defined. Therefore, we aimed to 
determine the degree of hepatocyte apoptosis and necrosis in PSC patients by measuring 
serum K18 and HMGB1 levels. Additionally, we examined the relationship between these 
markers and severity of PSC as assessed by liver biochemistries, liver histology, and PSC 
Mayo Risk Score [23]. In a subgroup of patients that underwent liver biopsy, we also 
assessed for apoptosis in the liver tissue using terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) assay.
MATERIALS AND METHODS
Study Cohort
This study consisted of 37 patients with well-characterized PSC, who had not undergone 
liver transplantation and 39 control subjects. Blood samples from PSC patients were 
collected as part of Indiana University-Purdue University at Indianapolis Institutional 
Review Board approved protocol with an informed consent. All samples were obtained over 
a two year period at the Indiana University Hepatology Clinic, Indianapolis, Indiana. The 
severity of PSC was assessed biochemically with serum hepatic panel [total bilirubin, 
alkaline phosphatase (AlkP), aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), albumin from the day of enrollment], histologically (METAVIR fibrosis score on 
liver biopsy), and Mayo PSC Risk Score based on the revised natural history model for 
primary sclerosing cholangitis [23]. Blood samples of 39 blood donors were obtained from 
Indiana blood bank (Indianapolis, Indiana) to serve as control subjects. These blood donors 
had (a) normal liver biochemistries, (b) negative serologic test for hepatitis B and C, (c) no 
significant co-morbidities, and (d) reported no alcohol consumption.
Measurement of caspase-generated K-18 Fragments in serum
Biosamples used in the current study were processed similarly to our previous published 
protocol [24]. M30, which is caspase-cleaved K18 fragment, a specific marker for apoptosis, 
were determined using M30-Apoptosense ELISA, per the manufacturer’s instructions 
(Peviva AB, Bromma, Sweden) [24]. Similarly, HMGB1 concentration in serum was 
measured by ELISA following the manufacturer’s protocol (IBL International, Hamburg, 
Germany). A serum aliquot of 25uL was used for the purpose of this study and absorbance 
was determined at 450nm with the Vmax Kinetic Microplate reader by Molecular Devices 
M2 (Sunnyvale, CA). Soft-max Pro software (version 6.2; Sunnyvale, CA) accompanying 
the microplate reader was used to generate the standard curve and determine the HMGB1 
values.
Quantification of hepatocyte apoptosis (through TUNEL assay)
TdT-mediated dUTP-X nick end labeling (TUNEL) assay was performed on a paraffin-
embedded sections using the Fluorescein In Situ Cell Death Detection Kit, POD combined 
with DAB substrate per the manufacturer’s protocol (Roche Applied Science, Indianapolis, 
IN). Hepatocyte apoptosis in liver sections was determined by counting the number of 
TUNEL positive cells in twenty representative 40x microscopic fields across the section and 
the total number of cells per field was determined by counting the number of nuclei present 
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in a representative quadrant and multiplying by four. The apoptotic index was calculated as 
the number of TUNEL positive cells per 400 cells.
Statistical analysis
Descriptive statistics such as means, standard deviation (SD), ranges and percentages were 
used to characterize the study patients. Comparisons among PSC and control groups were 
made by the use of non-parametric Mann-Whitney test for the continuous and χ2 test for the 
categorical variables. Pearson’s correlation coefficients were used to determine the degree of 
concordance between any two variables. Correlations were considered significant at the < 
0.05 level (2 tailed). Quality control procedures, database management, and statistical 
analyses were performed using IBM SPSS Statistics 20.0 (IBM Corporation, Armonk, NY).
RESULTS
The demographics, body mass index, and liver biochemistries of the PSC and control group 
are shown in Table 1. The study cohort was 67% male and 93% Caucasian. The mean age of 
the PSC cohort was slight older than the control group (51.0 ± 2.2 vs. 48.5 ± 13.4 years), but 
the difference was not statistically significant. Ulcerative colitis (UC) was present in 62% 
(n=23) of the PSC patients. As expected the liver biochemistries were all significantly 
elevated in PSC patients compared to the control subjects (p-val = <0.001). Serum K18 
levels were significantly elevated in the PSC patients compared to the control (217.4 ± 78.1 
vs. 157.0 ± 58.2 U/L, p-val = 0.001) (Table 1, Figure 1A). On the other hand, serum 
HMGB1 levels were not different between PSC and controls groups (5.38 ± 2.99 vs. 6.28 ± 
2.85 ng/mL, p-val = 0.15) (Table 1, Figure 1B). There was no significant correlation 
between serum levels of K18 and HMGB1 (r = −0.08, p-val =0.6).
Analysis to examine the relationship between serum K18 and liver biochemistries in the 
PSC cohort showed that serum K18 levels significantly correlated with AST (r = 0.4, p-val = 
0.016), Alk P (r = 0.5, p-val = 0.001), total bilirubin (r = 0.6, p-val =<0.001), and albumin (r 
= −0.4, p-val = 0.02) but not with ALT. Subgroup analysis in the PSC group between 
patients with and without ulcerative colitis showed elevated but not statistically significant 
serum K18 levels (234.4 ± 90.9 vs. 189.5 ± 68.4 U/L, p-val = 0.098) in those with UC. 
There were no significant differences in the liver biochemistries. In contrast, serum HMGB1 
levels were significantly lower in PSC patients with UC compared to those without (4.5 ± 
2.8 vs. 6.8 ± 2.9 ng/mL, p-val = 0.025).
To determine if the elevated K18 levels in the PSC cohort were due to apoptosis in the liver, 
we directly quantified apoptosis in the sections through TUNEL assay in patients who had 
previously undergone liver biopsy (n=16). The level of apoptosis present on the liver biopsy 
as assessed by the apoptotic index correlated with serum K18 levels (r=0.8, p-val <0.001) 
(Figure 2) but not with serum HMGB1 levels (r = 0.2, p-val = 0.4). Microscopic 
examination revealed the presence of apoptosis in hepatocytes and not in the biliary 
epithelium. There was no obvious zonality to the apoptosis. Histological data by liver biopsy 
with various stages of fibrosis [METAVIR classification: F0 (n=4), F1 (n=5), F2 (n=3), F3 
(n=8), and F4/cirrhosis (n=5)] was available in a subgroup of (n=25) PSC patients. Serum 
K18 levels were not significantly different among various degrees of fibrosis (p-val = 0.3).
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Lastly, we examined the correlation between serum K18 levels and the Mayo PSC Risk 
Score, a predictive model for patient survival that includes the variables of age, total 
bilirubin, albumin, AST, and history of variceal bleeding [23]. There was a strong negative 
correlation between K18 levels and Mayo PSC Risk Score (r=0.40, p-val = 0.015), i.e., 
higher serum K18 levels were associated with lower predicted survival.
DISCUSSION
Lack of effective therapies for PSC at the current time necessitate a better understanding of 
the mechanisms involved in the pathogenesis and progression of the disease. In the present 
study, increased serum K18 levels without a concomitant increase in HMGB1 levels support 
the important role of hepatocyte apoptosis in disease progression in individuals with PSC. 
Furthermore, the close correlation of serum K18 levels with several serum biochemical 
markers of liver disease severity and hepatocyte apoptotic index further supports the critical 
role of hepatocyte apoptosis in progression of disease in patients with PSC. It raises the 
possibility for use of K18 as a potential biomarker for disease severity in patients with PSC. 
Alternatively, it may even serve as a biomarker to assess response to therapy.
In the current study, the presence of apoptosis in the hepatocytes with no involvement of 
biliary epithelium suggests that the initial event of biliary structure from mechanisms that 
currently remain unclear result in hepatocyte cell death possibly through the inflammatory 
crosstalk between the reactive cholangiocytes and inflammatory cells promoting diffuse 
hepatocyte injury through apoptotic pathways. Liver-targeted caspase inhibitors could be an 
attractive treatment option for these patients and may be safely tolerated even in those with 
concomitant inflammatory bowel disease. Lastly, liver biopsy has a limited role in the 
evaluation and management of PSC due to asymmetrical involvement of biliary tract and 
heterogeneous fibrosis. In fact, Mayo Clinic Risk Score, the natural history model for 
prediction of survival in PSC patients was developed without the use of histologic staging 
[23]. Lack of relationship between serum K18 level and stage of fibrosis in the current study 
is therefore not a surprise.
A certain aspect of the current study may need further discussion. Keratin 18 is highly 
expressed in cholangiocytes but more moderately expressed in hepatocytes. Furthermore, it 
is also widely expressed throughout the intestine (http://www.proteinatlas.org/search/keratin
+18). Thus, it is possible that the elevated K18 could also originate from damaged intestinal 
epithelial cells. The higher levels of K18 present in serum of PSC+UC patients as compared 
to PSC-only patients (probably significant if larger cohorts would have been analyzed) could 
suggest that serum K18 instead partly originates from the intestine.
In summary, the current study suggests that hepatocyte apoptosis plays a predominant role 
in the pathogenesis of liver injury and disease progression in PSC. In future, longitudinal 
studies need to be performed with serial K18 measurements and examine its biomarker 
potential for disease progression or therapeutic response. Additional studies that would 
examine bile acid composition and cross-talk between reactive cholangiocytes and 
inflammatory cells would be very informative.
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Abbreviations
ALT Alanine aminotransferase
Alk P Alkaline phosphatase
AST Aspartate aminotransferase
HMGB1 High-mobility group protein B1
K18 Cytokeratin-18 fragment
PSC Primary sclerosing cholangitis
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling
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Figure 1. 
Serum levels of K18 and HMGB1 in PSC (n=37) and control (n=39) groups. (A) Serum K18 
levels were significantly elevated in PSC group when compared to control (217.4 ± 78.1 vs. 
157.0 ± 58.2 U/L, *p-val = 0.001). (B) Serum HMGB1 levels were not significantly 
different between the two groups (p-val = 0.15).
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Figure 2. 
Serum K18 levels correlated with the degree of apoptosis as quantified in the liver biopsy 
section through TUNEL assay (r=0.9, p-val = <0.001).
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Table 1
Demographics, liver biochemistries and serum markers of hepatocyte injury in patients with primary 
sclerosing cholangitis (PSC) and control subjects from healthy blood bank donors. All values are presented in 
mean ± standard deviation unless otherwise specified.
PSC (N=37) Controls (N=39) p-value
Demographics
Age (years) 51.0 ± 2.2 49 ± 13 0.43
Male (%) 57 77 0.1
Caucasian (%) 89 97 0.3
BMI (kg/m2) 28.3 ± 5.9 30.7 ± 6.6 0.19
Ulcerative colitis (%) 62% Not applicable
Liver biochemistries
Total Bilirubin (mg/dL) 2.07 ± 2.34 0.53 ± 0.19 <0.001
AST (U/L) 63 ± 37 24 ± 4 <0.001
ALT (U/L) 58 ± 35 17 ± 5 <0.001
Alkaline phosphatase (U/L) 306 ± 216 62 ± 12 <0.001
Markers of hepatocyte injury
Keratin 18 fragments (U/L) 217.39 ± 78.14 156.99 ± 58.17 0.001
HMGB1 (ng/mL) 5.38 ± 2.99 6.28 ± 2.85 0.15
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